Interpreting risk reduction in clinical trials for pulmonary arterial hypertension

European Respiratory Review : an Official Journal of the European Respiratory Society
Annie C LajoieSteeve Provencher

Abstract

Because of scepticism concerning study results when relying solely on relative effect estimates, the number needed to treat (NNT) has been used extensively to quantify the net clinical benefit of an intervention, and is reported increasingly in randomised trials and observational studies. This method is a simple measure representing the number of patients who would need to be treated to prevent one additional adverse event. However, like relative risk, the NNT is an inherently time-dependent measure. Thus, its calculation may lead to misleading interpretations, especially for studies involving varying follow-up times or recurrent outcomes. In addition to study duration and the efficacy of the therapy and the comparator, multiple other factors directly influence the NNT and should be taken into account in its interpretation as for comparative effectiveness of therapies. Its accurate estimation and interpretation, as well as its limitations, are therefore crucial to avoid erroneous clinical and public health decisions. We discuss the calculation and the interpretation of risk reduction and the NNT in the context of the changing landscape of clinical trials in pulmonary arterial hypertension.

References

Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Apr 2, 1998·BMJ : British Medical Journal·G H GuyattR S Goldstein
Oct 26, 1999·Lancet·L B Tan, R Murphy
Dec 3, 1999·BMJ : British Medical Journal·D G Altman, P K Andersen
Apr 6, 2004·The American Journal of Medicine·David A AlterAndreas Laupacis
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Spotswood L SpruanceMatthew Samore
Jan 25, 2008·Respiration; International Review of Thoracic Diseases·Steven D NathanKevin Leslie
Jan 22, 2009·European Heart Journal·Nazzareno GalièAngelo Branzi
Jul 9, 2009·Journal of the American College of Cardiology·Vallerie V McLaughlinWerner Seeger
Aug 6, 2011·Journal of Clinical Epidemiology·Daniel SuissaSamy Suissa
Jan 10, 2012·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Kasper Hasseriis AndersenJørn Carlsen
May 29, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Rowland J Bright-ThomasA Kevin Webb
Dec 22, 2012·Respiration; International Review of Thoracic Diseases·Motohiro KimuraYoshinori Hasegawa
Aug 30, 2013·The New England Journal of Medicine·Tomás PulidoUNKNOWN SERAPHIN Investigators
Jun 27, 2015·The European Respiratory Journal·Vallerie McLaughlinMarius M Hoeper
Aug 27, 2015·The New England Journal of Medicine·Nazzareno GalièUNKNOWN AMBITION Investigators
Dec 25, 2015·The New England Journal of Medicine·Olivier SitbonP G Williams
Mar 5, 2016·The Lancet. Respiratory Medicine·Annie Christine LajoieSteeve Provencher
Feb 16, 2018·Journal of the American College of Cardiology·Vallerie V McLaughlinNazzareno Galiè

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
C C MillerH J Safi
© 2022 Meta ULC. All rights reserved